Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Category

Sub-category

Conference

Consolidation durvalumab after cCRT shows decreased disease progression in LS...

Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands

Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC ( Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands )

Urine test could reduce post-op scans for kidney cancer by half

Dr Saeed Dabestani - Lund university, Lund, Sweden

Urine test could reduce post-op scans for kidney cancer by half ( Dr Saeed Dabestani - Lund university, Lund, Sweden )

Bone-protective agents given with enzalutamide with or without radium-223 show...

Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada

Bone-protective agents given with enzalutamide with or without radium-223 show greater survival benefits in mCRPC ( Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada )

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant...

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston...

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

Talazoparib and enzalutamide combination therapy shows significant benefit in...

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA

Talazoparib and enzalutamide combination therapy shows significant benefit in treating mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )

Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide...

Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center...

Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide alone in mCRPC ( Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center, Seattle, Washington )

Time to metastasis after prostatectomy should not be used as a prognostic...

Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA

Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC ( Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA )

SIOG 2024: Updates in medical oncology

Dr Capucine Baldini - Gustave Roussy, Villejuif, France

SIOG 2024: Updates in medical oncology ( Dr Capucine Baldini - Gustave Roussy, Villejuif, France )

ASCO GU 2025: Latest updates in mRCC

Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto...

ASCO GU 2025: Latest updates in mRCC ( Dr Bradley McGregor, Dr Stephanie Berg, Prof Viktor Grünwald and Prof Roberto Iacovelli )

Assessment and management of toxic effects of cancer therapy in elderly...

Dr Houda Belfekih - Mohamed Taher Maamouri Hospital, Nabeul, Tunisia

Assessment and management of toxic effects of cancer therapy in elderly patients in Tunisia ( Dr Houda Belfekih - Mohamed Taher Maamouri Hospital, Nabeul, Tunisia )

Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed...

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston...

Isatuximab survival benefit over VRd in transplant-ineligible newly diagnosed multiple myeloma ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

Daratumumab and lenalidomide for frail patients with newly diagnosed multiple...

Prof Salomon Manier - Hospital Center University De Lille, Lille, France

Daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma shows promising survival results ( Prof Salomon Manier - Hospital Center University De Lille, Lille, France )

More from ecancer